These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
249 related articles for article (PubMed ID: 29098416)
1. Neurological update: gliomas and other primary brain tumours in adults. Brandner S; Jaunmuktane Z J Neurol; 2018 Mar; 265(3):717-727. PubMed ID: 29098416 [TBL] [Abstract][Full Text] [Related]
2. Diagnostic algorithm for pathological evaluation of gliomas in a resource-constrained setting. Jain S; Gupta P; Shankar KB; Singh R; Siraj F J Cancer Res Ther; 2023; 19(3):562-566. PubMed ID: 37470575 [TBL] [Abstract][Full Text] [Related]
3. Diagnostic, prognostic and predictive relevance of molecular markers in gliomas. Brandner S; von Deimling A Neuropathol Appl Neurobiol; 2015 Oct; 41(6):694-720. PubMed ID: 25944653 [TBL] [Abstract][Full Text] [Related]
4. Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation. Brito C; Azevedo A; Esteves S; Marques AR; Martins C; Costa I; Mafra M; Bravo Marques JM; Roque L; Pojo M BMC Cancer; 2019 Oct; 19(1):968. PubMed ID: 31623593 [TBL] [Abstract][Full Text] [Related]
5. Molecular Diagnostic and Prognostic Subtyping of Gliomas in Tunisian Population. Trabelsi S; Chabchoub I; Ksira I; Karmeni N; Mama N; Kanoun S; Burford A; Jury A; Mackay A; Popov S; Bouaouina N; Ben Ahmed S; Mokni M; Tlili K; Krifa H; Yacoubi MT; Jones C; Saad A; H'mida Ben Brahim D Mol Neurobiol; 2017 May; 54(4):2381-2394. PubMed ID: 26957305 [TBL] [Abstract][Full Text] [Related]
6. Characterization of primary glioma cell lines derived from the patients according to 2016 CNS tumour WHO classification and comparison with their parental tumours. Oliva MA; Staffieri S; Castaldo S; Giangaspero F; Esposito V; Arcella A J Neurooncol; 2021 Jan; 151(2):123-133. PubMed ID: 33398536 [TBL] [Abstract][Full Text] [Related]
7. Immunohistochemistry on IDH 1/2, ATRX, p53 and Ki-67 substitute molecular genetic testing and predict patient prognosis in grade III adult diffuse gliomas. Takano S; Ishikawa E; Sakamoto N; Matsuda M; Akutsu H; Noguchi M; Kato Y; Yamamoto T; Matsumura A Brain Tumor Pathol; 2016 Apr; 33(2):107-16. PubMed ID: 26968173 [TBL] [Abstract][Full Text] [Related]
9. ATRX immunostaining predicts IDH and H3F3A status in gliomas. Ebrahimi A; Skardelly M; Bonzheim I; Ott I; Mühleisen H; Eckert F; Tabatabai G; Schittenhelm J Acta Neuropathol Commun; 2016 Jun; 4(1):60. PubMed ID: 27311324 [TBL] [Abstract][Full Text] [Related]
10. Characterization of gliomas: from morphology to molecules. Ferris SP; Hofmann JW; Solomon DA; Perry A Virchows Arch; 2017 Aug; 471(2):257-269. PubMed ID: 28674742 [TBL] [Abstract][Full Text] [Related]
11. Thirty years of progress in the management of low-grade gliomas. van den Bent MJ Rev Neurol (Paris); 2023 Jun; 179(5):425-429. PubMed ID: 37029057 [TBL] [Abstract][Full Text] [Related]
12. New Molecular Considerations for Glioma: IDH, ATRX, BRAF, TERT, H3 K27M. Karsy M; Guan J; Cohen AL; Jensen RL; Colman H Curr Neurol Neurosci Rep; 2017 Feb; 17(2):19. PubMed ID: 28271343 [TBL] [Abstract][Full Text] [Related]
13. Low FoxG1 and high Olig-2 labelling indices define a prognostically favourable subset in isocitrate dehydrogenase (IDH)-mutant gliomas. Schäfer S; Behling F; Skardelly M; Koch M; Ott I; Paulsen F; Tabatabai G; Schittenhelm J Neuropathol Appl Neurobiol; 2018 Feb; 44(2):207-223. PubMed ID: 29053887 [TBL] [Abstract][Full Text] [Related]
14. Analysis of isocitrate dehydrogenase 1 mutation in 97 patients with glioma. Zhou YX; Wang JX; Feng M; Sun CM; Sun T; Chen GL; Du ZW J Mol Neurosci; 2012 Jul; 47(3):442-7. PubMed ID: 22113362 [TBL] [Abstract][Full Text] [Related]
15. SEOM-GEINO clinical guidelines for high-grade gliomas of adulthood (2022). Segura PP; Quintela NV; García MM; Del Barco Berrón S; Sarrió RG; Gómez JG; Castaño AG; Martín LMN; Rubio OG; Losada EP Clin Transl Oncol; 2023 Sep; 25(9):2634-2646. PubMed ID: 37540408 [TBL] [Abstract][Full Text] [Related]
16. Further understanding of the pathology of glioma: implications for the clinic. Camelo-Piragua S; Kesari S Expert Rev Neurother; 2016 Sep; 16(9):1055-65. PubMed ID: 27228211 [TBL] [Abstract][Full Text] [Related]
17. Diagnostic revision of 206 adult gliomas (including 40 oligoastrocytomas) based on ATRX, IDH1/2 and 1p/19q status. Mellai M; Annovazzi L; Senetta R; Dell'Aglio C; Mazzucco M; Cassoni P; Schiffer D J Neurooncol; 2017 Jan; 131(2):213-222. PubMed ID: 27796734 [TBL] [Abstract][Full Text] [Related]
18. Integrated diagnostics of diffuse astrocytic and oligodendroglial tumors. Malzkorn B; Reifenberger G Pathologe; 2019 Jun; 40(Suppl 1):9-17. PubMed ID: 31025086 [TBL] [Abstract][Full Text] [Related]
19. Gliomas molecular markers: importance in treatment, prognosis and applicability in brazilian health system. Soldatelli JS; Oliveira IM; Kneubil MC; Henriques JAP An Acad Bras Cienc; 2022; 94(3):e20211075. PubMed ID: 35766600 [TBL] [Abstract][Full Text] [Related]
20. IDH mutation, 1p19q codeletion and ATRX loss in WHO grade II gliomas. Leeper HE; Caron AA; Decker PA; Jenkins RB; Lachance DH; Giannini C Oncotarget; 2015 Oct; 6(30):30295-305. PubMed ID: 26210286 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]